Wuhan Hiteck Biological Pharma Co.,Ltd (SHE:300683)
China · Delayed Price · Currency is CNY 23.62
+0.62 (2.70%)
Oct 23, 2026, 3:04 PM CST
SHE:300683 Financials Overview
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Revenue Revenue Growth | 433.31 | 541.45 | 648.97 | 602.28 | 688.63 | 614.68 |
Revenue Growth | -30.10% | -16.57% | 7.75% | -12.54% | 12.03% | 17.28% |
Gross Profit Gross Profit Growth | 136.66 | 217.22 | 268.09 | 232.56 | 329.75 | 349.82 |
Operating Income Operating Income Growth | -204.1 | -161.09 | -116.08 | -139.54 | -33.69 | -13.2 |
Net Income Net Income Growth | -192.44 | -231.27 | -69.35 | -120.82 | -14.03 | 27.65 |
Earnings Per Share EPS Growth | -1.47 | -1.77 | -0.53 | -0.93 | -0.11 | 0.26 |
EPS Growth | - | - | - | - | - | - |
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Production and Sales of Raw Materials and Pharmaceutical Intermediates Production and Sales of Raw Materials and Pharmaceutical Intermediates Growth | 64.72 | 53.41 | 48.8 | 200.72 | 102.26 |
in Vitro Diagnostic Reagents in Vitro Diagnostic Reagents Growth | 4.17 | - | - | - | - |
Medical Technical Services Reporting Segment Medical Technical Services Reporting Segment Growth | 257.25 | 422.82 | 390.7 | 319.4 | 281.29 |
Other Other Growth | 9.07 | 11.69 | 5.08 | 9.85 | 45.39 |
Biopharma Biopharma Growth | 231.95 | 161.05 | 157.7 | 158.65 | 185.75 |
offset of business segment offset of business segment Growth | -25.71 | - | - | - | - |
Total Total Growth | 541.45 | 648.97 | 602.28 | 688.63 | 614.68 |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Cash & Investments Cash & Investments Growth | 368.7 | 821.19 | 873.4 | 1,089 | 1,035 | 1,190 |
Total Debt Total Debt Growth | 34.41 | 33.26 | 44.05 | 63.5 | 81.55 | 89.92 |
Net Cash (Debt) Net Cash Growth | 334.29 | 787.93 | 829.35 | 1,026 | 953.73 | 1,100 |
Net Cash Growth | -51.17% | -4.99% | -19.14% | 7.55% | -13.29% | 10.72% |
Net Cash Per Share Net Cash Per Share Growth | 2.55 | 6.03 | 6.34 | 7.90 | 7.48 | 10.34 |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Cash Flow Operating Cash Flow Growth | -6.66 | -76.54 | 22.69 | 5.31 | 53.03 | 12.09 |
Capital Expenditures CapEx Growth | -26.91 | -50.54 | -43.08 | -167.44 | -173.97 | -247.11 |
Free Cash Flow Free Cash Flow Growth | -33.56 | -127.07 | -20.39 | -162.13 | -120.94 | -235.02 |
Free Cash Flow Growth | - | - | - | - | - | - |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Gross Margin | 31.54% | 40.12% | 41.31% | 38.61% | 47.88% | 56.91% |
Operating Margin | -47.10% | -29.75% | -17.89% | -23.17% | -4.89% | -2.15% |
Pretax Margin | -46.62% | -44.10% | -12.35% | -25.23% | -1.14% | 3.33% |
Profit Margin | -44.41% | -42.71% | -10.69% | -20.06% | -2.04% | 4.50% |
FCF Margin | -7.75% | -23.47% | -3.14% | -26.92% | -17.56% | -38.23% |
Fiscal Year | FY 2024 |
|---|---|
| Period Ending | Dec '24 Dec 31, 2024 |
Dividend Per Share Dividend Per Share Growth | 0.130 |
Dividend Per Share Growth | - |
Dividend Yield | 0.55% |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Oct '26 Oct 24, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | - | - | - | - | - | 262.98 |
Forward PE | - | 21.83 | 21.83 | 21.83 | 21.83 | 21.83 |
PS Ratio | 7.14 | 6.70 | 4.81 | 7.85 | 6.28 | 11.83 |